Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Phase 1

Completed

Conditions: Oncology

Interventions: Drug: AZD9291
Drug: [14C]AZD9291

First Posted Date: 2015-07-08

Last Posted Date: 2016-10-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT02491944

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Interferon beta-1a Nebuliser solution 48 μg/mL
Drug: Placebo

First Posted Date: 2015-07-08

Last Posted Date: 2019-02-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 121

Registration Number: NCT02491684

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Phase 1

Completed

Conditions: Safety
Tolerability
Pharmacokinetics
Healthy Subjects

Interventions: Drug: AZD9977, oral suspension
Drug: Placebo, oral suspension
Drug: AZD9977, oral solution

First Posted Date: 2015-06-30

Last Posted Date: 2017-04-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 196

Registration Number: NCT02484729

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

Interventions: Drug: AZD 1775

First Posted Date: 2015-06-26

Last Posted Date: 2023-07-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 92

Registration Number: NCT02482311

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Ticagrelor
Drug: Placebo

First Posted Date: 2015-06-26

Last Posted Date: 2018-12-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 87

Registration Number: NCT02482298

Locations: 🇬🇧
Research Site, London, United Kingdom

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Phase 2

Completed

Conditions: Asthma
Efficacy
Safety

Interventions: Drug: 250 µg AZD7594 once daily
Drug: 800 μg AZD7594 once daily
Drug: 58 µg AZD7594 once daily
Drug: Placebo once daily
Drug: Salbutamol

First Posted Date: 2015-06-24

Last Posted Date: 2018-02-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT02479412

Locations: 🇩🇪
Research Site, Wiesbaden, Germany

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Phase 4

Completed

Conditions: BRCA or HRR+ Mutated Ovarian Cancer Patients

Interventions: Drug: Olaparib

First Posted Date: 2015-06-22

Last Posted Date: 2022-09-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 181

Registration Number: NCT02476968

Locations: 🇬🇧
Research Site, Wirral, United Kingdom

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Completed

Conditions: Reflux Esophagitis

First Posted Date: 2015-06-22

Last Posted Date: 2017-06-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 1595

Registration Number: NCT02477475

Locations: 🇯🇵
Research Site, Yamanashi, Japan

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2015-06-19

Last Posted Date: 2017-03-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 2000

Registration Number: NCT02475720

Locations: 🇯🇵
Izumi Municipal Hospital, Izumi, Osaka, Japan

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Procedure: T790M+ Testing
Procedure: Baseline Visit Blood & Urine Testing
Procedure: Baseline ECG
Procedure: Visual Slit-Lamp Testing
Drug: AZD9291 Dosing

First Posted Date: 2015-06-17

Last Posted Date: 2021-11-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 3017

Registration Number: NCT02474355

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy